Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers... Show more
Cardinal Health's fiscal first quarter, which ended September 30, 2026, offers an important read on the health of pharmaceutical distribution and medical supplies demand. As a low-margin distributor, the company's profitability depends heavily on operating leverage and the performance of its higher-margin specialty and growth businesses. The quarter was closely watched for progress in the Global Medical Products and Distribution unit, which has faced margin pressure, and for momentum in specialty pharmaceuticals. Strong demand across the enterprise, combined with disciplined cost execution, gave management enough confidence to raise its full-year outlook—a signal that resonates broadly for investors tracking the healthcare supply chain.
Cardinal Health reported first-quarter fiscal 2027 revenue of $67.5 billion, up 5% year over year and above consensus expectations. Non-GAAP diluted EPS came in at $3.26, a 28% year-over-year increase that surpassed the analyst consensus estimate of roughly $2.92–$2.94. On a GAAP basis, diluted EPS rose 27% to $2.38.
Adjusted operating income increased 17% to $1.0 billion, marking the first time the company has reached that milestone in a single quarter. Within the segments, Pharmaceutical and Specialty Solutions revenue rose 6% to $62.6 billion, with segment profit up 17% to $783 million. Global Medical Products and Distribution revenue was roughly flat at $3.2 billion, while segment profit fell 28% to $33 million. The Other segment, which houses the company's growth businesses, grew revenue 7% to $1.8 billion and profit 16% to $193 million.
Management raised its fiscal 2027 adjusted EPS guidance to $12.80–$13.00, from the prior range of $12.40–$12.60, citing robust demand and strong operational execution.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Whether you are tracking earnings movers like Cardinal Health or exploring broader sector themes, the AI Screener can help you narrow your focus and spot potential setups.
Shares of Cardinal Health climbed on the day of the report, rising roughly 5.75% to about $276.99 after the company beat expectations and lifted its outlook. The positive reaction reflected investor approval of the earnings beat and the guidance raise, particularly the strength in the high-margin specialty and growth businesses. Sentiment was also supported by the company's balance-sheet actions, including the completed $500 million accelerated share repurchase. While the Global Medical Products and Distribution segment remained a soft spot, management's acknowledgment of external cost pressures, including petroleum-related transportation costs, did not meaningfully dampen the broader enthusiasm around the quarter.
Looking ahead, investors will watch whether Cardinal Health can sustain the operating leverage that powered its first quarter. The raised fiscal 2027 adjusted EPS guidance of $12.80–$13.00 implies continued profit momentum, but execution will matter across each segment.
In the Pharmaceutical and Specialty Solutions segment, key factors include specialty sales growth, the performance of the generics program, and the ongoing impact of GLP-1 medication volume. Management also signaled that the contribution from the Solaris acquisition will be lapped beginning in the second quarter, which could affect year-over-year comparisons.
For Global Medical Products and Distribution, the focus remains on margin recovery. Management noted that sustained high petroleum costs could push segment profit toward the low end of its $200 million–$220 million guidance range. Meanwhile, the growth businesses within the Other segment continue to benefit from secular trends such as an aging population and the shift toward home-based care.
Beyond operations, investors may monitor the anticipated completion of the AdaptHealth Diabetes Health acquisition in the third quarter of fiscal 2027 and the renewed pharmaceutical distribution agreements with CVS Health. These developments could shape both revenue growth and competitive positioning in the coming quarters.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a maker of pharmaceuticals, medical, surgical and laboratory supplies as well as develops drug delivery systems
Industry MedicalDistributors